Nature Medicine: REMODEL RCT probes how weekly semaglutide 1 mg may protect kidneys in T2D+CKD

On 1 October 2026, Nature Medicine published the REMODEL trial: a 52-week randomised, placebo-controlled study of subcutaneous semaglutide 1 mg once weekly versus placebo in people with type 2 diabetes and chronic kidney disease (n = 106; 71 semaglutide, 35 placebo; ClinicalTrials.gov NCT04865770). The aim was to probe kidney-specific mechanisms behind clinical kidney protection seen with semaglutide (including the larger FLOW outcomes trial), using multiparametric kidney MRI, histology and single-nucleus/spatial transcriptomics on paired biopsies in a subset.

Primary vs secondary findings

The coprimary MRI outcomes — cortical oxygenation (R2*), global kidney perfusion and T1 mapping as an inflammation-related marker — were not significantly altered by semaglutide versus placebo at week 52. Secondary imaging findings included a significantly reduced renal artery resistive index (RARI) (estimated treatment ratio 0.96, 95% CI 0.93–0.99; P = 0.008) and higher cortical apparent diffusion coefficient (ADC) signals interpreted as attenuating fibrosis progression. Transcriptomic secondary analyses highlighted effects on glomerular endothelial cell programmes and fewer nearby immune cells in spatial analyses. Exploratory clinical signals included roughly 40% lower UACR versus placebo and higher 24-hour creatinine clearance; body weight and HbA1c also fell more with semaglutide, as expected for the drug class.

Limitations and context

Authors note an exploratory design, no formal multiplicity hierarchy for many outcomes, optimistic power assumptions for R2*, under-representation of women, and a small biopsy/transcriptomic subset — so associations should not be over-interpreted as proven causal pathways. Sponsor Novo Nordisk funded the trial. This summarises a mechanistic RCT with mixed primary/secondary results; it is not personal medical advice. Talk to a doctor about approved therapies for diabetes and kidney disease.